Mackenzie Financial Corp Sells 1,813 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Mackenzie Financial Corp decreased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 31.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,943 shares of the company’s stock after selling 1,813 shares during the quarter. Mackenzie Financial Corp’s holdings in Vaxcyte were worth $248,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in PCVX. Westfield Capital Management Co. LP bought a new stake in Vaxcyte during the 3rd quarter valued at approximately $51,180,000. Eventide Asset Management LLC bought a new stake in Vaxcyte during the 3rd quarter valued at approximately $20,035,000. Jennison Associates LLC boosted its stake in Vaxcyte by 20.6% during the 3rd quarter. Jennison Associates LLC now owns 1,754,691 shares of the company’s stock valued at $89,454,000 after purchasing an additional 300,189 shares during the period. Wellington Management Group LLP boosted its stake in Vaxcyte by 3.8% during the 3rd quarter. Wellington Management Group LLP now owns 4,598,712 shares of the company’s stock valued at $234,442,000 after purchasing an additional 167,501 shares during the period. Finally, Moody Aldrich Partners LLC boosted its stake in Vaxcyte by 468.3% during the 3rd quarter. Moody Aldrich Partners LLC now owns 140,170 shares of the company’s stock valued at $7,146,000 after purchasing an additional 115,505 shares during the period. Institutional investors own 96.78% of the company’s stock.

Insider Transactions at Vaxcyte

In other news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction that occurred on Thursday, April 18th. The stock was sold at an average price of $61.27, for a total value of $490,160.00. Following the completion of the transaction, the chief financial officer now directly owns 95,679 shares of the company’s stock, valued at approximately $5,862,252.33. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $61.27, for a total transaction of $490,160.00. Following the completion of the sale, the chief financial officer now directly owns 95,679 shares of the company’s stock, valued at approximately $5,862,252.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Mikhail Eydelman sold 1,667 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $73.87, for a total value of $123,141.29. Following the sale, the senior vice president now directly owns 20,710 shares of the company’s stock, valued at $1,529,847.70. The disclosure for this sale can be found here. In the last ninety days, insiders sold 75,577 shares of company stock valued at $5,149,735. Corporate insiders own 3.60% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on PCVX. Bank of America upped their price target on Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $95.00 price target on shares of Vaxcyte in a report on Wednesday, April 10th. Four research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $78.50.

Vaxcyte Trading Up 1.1 %

Shares of PCVX opened at $60.72 on Monday. Vaxcyte, Inc. has a 1 year low of $41.57 and a 1 year high of $82.04. The stock has a 50 day simple moving average of $67.96 and a 200-day simple moving average of $61.53. The stock has a market cap of $6.60 billion, a PE ratio of -14.70 and a beta of 0.89.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same period last year, the business earned ($0.73) earnings per share. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.18 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.